Cameron OMara - Dignitana Exec Sales
| DIGN Stock | SEK 1.19 0.01 0.83% |
Insider
Cameron OMara is Exec Sales of Dignitana AB
| Age | 44 |
| Phone | 46 46 16 30 90 |
| Web | https://dignitana.com |
Dignitana Management Efficiency
The company has return on total asset (ROA) of (0.2464) % which means that it has lost $0.2464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7786) %, meaning that it generated substantial loss on money invested by shareholders. Dignitana's management efficiency ratios could be used to measure how well Dignitana manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Stuart Rowling | Paxman AB | 41 | |
| Emma Thornhill | Paxman AB | 38 | |
| Patrick Burke | Paxman AB | 64 | |
| Pal Ryfors | Episurf Medical AB | 40 | |
| Priscilla Kazumba | C Rad AB | N/A | |
| Dan Mogren | Clinical Laserthermia Systems | N/A | |
| Veronica Wallin | Episurf Medical AB | 37 | |
| Claire Paxman | Paxman AB | 45 | |
| Katarina Flodstrm | Episurf Medical AB | 48 | |
| Emelie Gustafsson | Paxman AB | 43 | |
| Emelie Gozzi | C Rad AB | N/A | |
| Richard Paxman | Paxman AB | 40 | |
| Xiaodong Wang | C Rad AB | 44 | |
| Stephen Caswell | Episurf Medical AB | 42 | |
| Liza Hirst | Paxman AB | 49 | |
| Alexandra Sheldrake | Paxman AB | 38 | |
| Lars Levin | C Rad AB | 52 | |
| Rolf Bornschein | Clinical Laserthermia Systems | N/A | |
| Patrick Jamnik | Episurf Medical AB | 40 | |
| Tim Thurn | C Rad AB | 42 | |
| Michael Nsstrm | Episurf Medical AB | 34 | |
Management Performance
| Return On Equity | -0.78 | |||
| Return On Asset | -0.25 |
Dignitana AB Leadership Team
Elected by the shareholders, the Dignitana's board of directors comprises two types of representatives: Dignitana inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dignitana. The board's role is to monitor Dignitana's management team and ensure that shareholders' interests are well served. Dignitana's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dignitana's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James McKinney, President, Chief Operating Officer | ||
| Mikael Wahlgren, Deputy Managing Director, Director | ||
| Anette Cronstroem, Ex Officer | ||
| Karin Liwendahl, Chief Financial Officer | ||
| Ulf Jonsson, Chief Officer | ||
| Mary Hatcher, Chief Financial Officer | ||
| Josephine Divers, Vice President Clinical Oncology Services | ||
| Greg Dingizian, Director | ||
| Jonas Sohlman, Interim Chief Financial Officer | ||
| Darren Henderson, Vice President Quality and Regulatory Affairs | ||
| Johan Johansson, RD Operations | ||
| Pontus Kristiansson, Director | ||
| Jane Wall, Director Services | ||
| Thomas Joyce, Ex Officer | ||
| Ingrid Heiman, Director | ||
| Bill Leuchten, Group Vice President Sales | ||
| Catarina Lwenadler, Chief Officer | ||
| Thomas Kelly, Chairman of the Board | ||
| Cameron OMara, Exec Sales | ||
| Christian Lindgren, VP Director | ||
| William Cronin, Chief Executive Officer, Director | ||
| Melissa Bourestom, Vice President Marketing, Talent and Investor Relations |
Dignitana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dignitana a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (0.32) % | |||
| Operating Margin | (0.41) % | |||
| Current Valuation | 390.26 M | |||
| Shares Outstanding | 70.47 M | |||
| Shares Owned By Insiders | 12.68 % | |||
| Shares Owned By Institutions | 42.71 % | |||
| Price To Earning | (4.88) X | |||
| Price To Book | 30.36 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Dignitana Stock Analysis
When running Dignitana's price analysis, check to measure Dignitana's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dignitana is operating at the current time. Most of Dignitana's value examination focuses on studying past and present price action to predict the probability of Dignitana's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dignitana's price. Additionally, you may evaluate how the addition of Dignitana to your portfolios can decrease your overall portfolio volatility.